New research from the University of Bath shows that for older patients with atrial fibrillation, stopping blood thinning medication can be far more dangerous than the potential risk of bleeding.
Atrial fibrillation, often called AF, is a common heart condition in which the heart beats irregularly.
This irregular beating can cause blood to pool and form clots, which in turn can travel to the brain and cause a stroke. In the United Kingdom alone, AF is linked to around 20,000 strokes every year.
For many years, doctors have been very careful when prescribing blood thinners to older people because of concerns about falls and severe bleeding. However, the latest study suggests that the dangers of stopping these medications are much greater than previously thought.
For many older patients, blood thinners, also known as anticoagulants, play a vital role in preventing strokes, heart attacks, and even death. The idea behind using these medications is to keep the blood from clotting too easily, which is especially important for patients with AF.
Even though older individuals are more prone to falling, which can sometimes lead to serious injuries like hip fractures or head injuries, the research indicates that the risk of a life-threatening bleed does not significantly increase when these medications are stopped.
Instead, the study found that when patients aged 75 and over are not taking anticoagulants, their risk of stroke and death triples, and the risk of heart attacks nearly doubles.
The study looked at real patient data from a large UK database collected between 2013 and 2017. Researchers focused on patients over the age of 75 who were newly prescribed blood thinners.
By comparing periods when these patients were on medication with times when they had stopped taking their anticoagulants, the researchers could clearly see the effects of not being treated.
Their findings showed that the benefits of continuing anticoagulant therapy far outweigh the risks of major bleeding. In other words, even if a patient is at risk of falls, the protection provided by these drugs against stroke and heart attack is much more important.
Historically, many doctors have been cautious about using blood thinners like warfarin in older patients. Warfarin was the only drug available for many years to manage AF, but it comes with a number of challenges. Patients taking warfarin often have to deal with strict dietary restrictions, regular blood tests, and a complicated dosing schedule.
These factors made it difficult for many older patients to stick with the treatment. However, since 2013, a new group of drugs known as direct oral anticoagulants (DOACs) has become the preferred choice for many patients.
DOACs are easier to use and have been shown to be just as effective, if not more so, than warfarin. For example, the DOAC apixaban has a lower risk of causing significant bleeding, making it a very attractive option for older patients with AF.
Doctors like Dr. Anneka Mitchell from the University of Bath have pointed out that stopping blood thinning medication can leave patients more vulnerable to stroke and other serious heart-related problems. Dr. Mitchell and her colleagues used a large dataset from UK general practices to measure patient outcomes when anticoagulants were stopped.
Their careful analysis of over 20,000 older patients provided strong evidence that the risk of adverse events like stroke and death rises significantly without continuous treatment.
This is important because it helps both doctors and patients better understand the real dangers involved. With these findings, clinicians are now encouraged to weigh the benefits of preventing blood clots against the relatively small risk of bleeding, even for patients who might fall.
The study’s results also remind us that older patients have often been underrepresented in clinical trials for newer medications like DOACs. Many of the early trials included only healthier older individuals, which meant that doctors had limited evidence about how these drugs would work in the wider, more vulnerable elderly population.
By using real-world data from thousands of patients, this research fills an important gap in our understanding of how to safely manage atrial fibrillation in older adults.
In reviewing the study, it becomes clear that the risks associated with stopping anticoagulant therapy are substantial. The evidence indicates that the increased risk of stroke, heart attack, and death far outweighs the potential for major bleeding.
This research provides critical information that can help guide shared decision-making between doctors and their older patients. It emphasizes that while concerns about falls and bleeding are understandable, the real threat lies in leaving atrial fibrillation untreated.
The findings support the idea that clinicians should continue prescribing blood thinners, particularly the newer and easier-to-manage DOACs, to help protect older patients from serious cardiovascular events.
Overall, the study offers a strong case for maintaining anticoagulation therapy in elderly patients, ensuring they receive the most effective care to reduce the risk of life-altering complications.
Copyright © 2025 Knowridge Science Report. All rights reserved.
